Arcellx (ACLX) Interest & Investment Income (2024 - 2025)
Arcellx's quarterly Interest & Investment Income came in at $5.6 million in Q4 2025, down 26.16% year-on-year from $7.6 million in Q4 2024, and down 6.61% quarter-over-quarter from $6.0 million in Q3 2025.
Arcellx has reported Interest & Investment Income for 2 years, with the latest figure at $5.6 million in Q4 2025.
- For the quarter ending Q4 2025, Interest & Investment Income fell 26.16% year-over-year to $5.6 million; the trailing twelve-month figure through Dec 2025 stood at $24.2 million (down 27.32% YoY), and the FY2025 full-year result was $24.2 million, down 27.32% from the prior year.
- Interest & Investment Income for Q4 2025 stood at $5.6 million, down from $6.0 million in the prior quarter.
- The five-year high for Interest & Investment Income was $9.2 million in Q1 2024, with the low at $5.6 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 5.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.60 Mn |
| Sep 30, 2025 | 6.00 Mn |
| Jun 30, 2025 | 5.98 Mn |
| Mar 31, 2025 | 6.64 Mn |
| Dec 31, 2024 | 7.58 Mn |
| Sep 30, 2024 | 8.09 Mn |
| Jun 30, 2024 | 8.45 Mn |
| Mar 31, 2024 | 9.20 Mn |